Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]PiB + [18F]DPA-714
- Development stage
- Preclinical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[11C]PiB (Pittsburgh Compound B) and [18F]DPA-714 are radiopharmaceuticals used together in positron emission tomography (PET) imaging studies, particularly for Alzheimer's disease research. [11C]PiB binds to amyloid-beta plaques, while [18F]DPA-714 is a radiotracer that targets the 18-kDa translocator protein (TSPO), which is overexpressed in activated microglia during neuroinflammation. This combination allows researchers to simultaneously assess amyloid plaque burden and neuroinflammatory processes in the brain[2][3][9].
02
Targets
TSPO (Translocator Protein (18 kDa))Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on [11C]PiB + [18F]DPA-714.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [11C]PiB + [18F]DPA-714.